- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07709858
CHATEAU Registry: Clinical Outcomes After Transcatheter Aortic Valve Replacement (CHATEAU)
Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement: The Collaborative Hexagon-Asian Transcatheter Aortic Valve Replacement Union (CHATEAU) Registry
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The CHATEAU Registry is an international, multicenter, observational registry of patients undergoing transcatheter aortic valve replacement. This study will retrospectively analyze consecutive 4,000 patients treated with TAVR at participating centers from January 1, 2021 to December 31, 2025. Follow-up clinical outcomes will be assessed through December 31, 2027.
Eligible patients are adults who underwent TAVR for aortic valve disease. Data will be collected from existing medical records, including baseline demographics, comorbidities, laboratory findings, pre-procedural imaging data, procedural details, device information, post-procedural echocardiographic findings, discharge medications, and clinical follow-up outcomes.
The study aims to evaluate the association between patient-, anatomy-, device-, and procedure-related factors and subsequent clinical outcomes and valve performance. Outcomes of interest may include all-cause death, cardiovascular death, stroke, myocardial infarction, heart failure hospitalization, pacemaker implantation, valve hemodynamic deterioration, aortic valve reintervention, paravalvular regurgitation, and other TAVR-related clinical events.
Because this is a retrospective observational study, all treatment decisions were made according to routine clinical practice at each participating institution. The study does not involve randomization, assignment of treatment, additional procedures, or additional patient visits. All data will be handled in accordance with applicable institutional review board requirements and privacy regulations.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Osung Kwon, MD. PhD
- Telefonnummer: +821037085673
- E-post: oscaesar@gmail.com
Studieorter
-
-
-
Seoul, Sydkorea, 03312
- Rekrytering
- The Catholic University of Korea, Eunpyeong St. Mary's Hospital
-
Kontakt:
- Osung Kwon, MD, PhD
- Telefonnummer: +821037085673
- E-post: oscaesar@gmail.com
-
Kontakt:
- E-post: oscaesar@gmail.com
-
Huvudutredare:
- Osung Kwon, MD, PhD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Adults (≥18 years of age).
- Patients who underwent transcatheter aortic valve replacement (TAVR) for severe native aortic valve disease at participating centers.
- TAVR performed between January 1, 2021 and December 31, 2025.
- Availability of baseline procedural and follow-up clinical data in the institutional registry or medical records.
Exclusion Criteria:
- Patients with insufficient clinical or procedural data for outcome assessment.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
CHATEAU Registry Cohort
Consecutive adult patients with severe aortic valve disease who underwent transcatheter aortic valve replacement (TAVR) between January 1, 2021 and December 31, 2025 at participating centers in the CHATEAU Registry.
Clinical, imaging, procedural, and follow-up data are collected retrospectively from routine clinical practice.
|
Transcatheter aortic valve replacement (TAVR) performed according to routine clinical practice using commercially available transcatheter heart valves and standard procedural techniques at participating centers.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
All-Cause Mortality
Tidsram: From the index TAVR procedure through December 31, 2027 (up to approximately 6 years)
|
Death from any cause occurring after transcatheter aortic valve replacement (TAVR) during follow-up.
|
From the index TAVR procedure through December 31, 2027 (up to approximately 6 years)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Cardiovascular Mortality Stroke Heart Failure Hospitalization Myocardial Infarction Aortic Valve Reintervention Valve Hemodynamic Deterioration Prosthetic Valve Endocarditis/thrombosis Permanent pace maker insertion Major Bleeding
Tidsram: From the index TAVR procedure through December 31, 2027 (up to approximately 6 years)
|
Outcome events will be assessed during follow-up using routinely collected clinical and imaging data.
Clinical events will be defined according to the Valve Academic Research Consortium-3 (VARC-3) criteria, where applicable, and adjudicated according to each participating center's standard clinical practice.
|
From the index TAVR procedure through December 31, 2027 (up to approximately 6 years)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Osung Kwon, MD, PhD, The Catholic University of Korea Eunpyeong St. Mary's Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Aortaklaffssjukdom
- Hjärt-kärlsjukdomar
- Hjärtsjukdom
- Hjärtklaffssjukdomar
- Ventrikulärt utflödeshinder
- Aortaklaffstenos
- Kirurgiska ingrepp, operativ
- Hjärtkirurgiska ingrepp
- Hjärtkirurgiska ingrepp
- Thoraxkirurgiska ingrepp
- Protesimplantation
- Hjärtventilprotesimplantation
- Transkateter aortaventilersättning
Andra studie-ID-nummer
- CHATEAU-REG-001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .